TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22101890

Group type: EXPERIMENTAL
Intervention: Female adult film performers
Number of subjects: 134

Group type: COMPARATOR
Intervention: California women
Number of subjects: 134
Study: 22221685

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Face Mask (FM)
Number of subjects: 150
Study: 19341577

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Auto‐polymerized resin‐based sealant (RBS)
Number of subjects: 36
Study: 17213873

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure fell with hemodialysis (DeltaSBP <= -10 mm Hg)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Systolic blood pressure remained unchanged with hemodialysis (DeltaSBP -10 to 10 mm Hg)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Systolic blood pressure rose with hemodialysis (DeltaSBP >= 10 mm Hg)
Number of subjects: 443
Study: 16827252

Group type: EXPERIMENTAL
Intervention: Buprenorphine 30 micrograms with hyperbaric bupivacaine 0.75% 2 ml (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms with hyperbaric bupivacaine 0.75% 2 ml (group F)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 0.75% 2 ml (group L control)
Number of subjects: 60
Study: 12811695

Group type: EXPERIMENTAL
Intervention: CT-guided intra-articular corticosteroid injection (low-dose injection)
Number of subjects: 89

Group type: COMPARATOR
Intervention: NSAIDs therapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Dynamic MRI follow-up
Number of subjects: 89
Study: 9927354

Group type: EXPERIMENTAL
Intervention: Bradykinin (BK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Des‐Arg10‐lysylbradykinin
Number of subjects: 0
Study: 7762835

Group type: EXPERIMENTAL
Intervention: Fentanyl 50 micrograms and propofol 35 mg (FP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fentanyl 50 micrograms and midazolam 2 mg (FM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fentanyl 50 micrograms, midazolam 2 mg, and propofol 35 mg (FMP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol 56 g (orally administered)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 12
Study: 2113967

Group type: EXPERIMENTAL
Intervention: 300 mg DOPS
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 600 mg DOPS
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 105656

Group type: EXPERIMENTAL
Intervention: Low-dose insulin regimen (0.44 U/kg body weight loading dose half intramuscularly and half intravenously followed by 7 U/h intramuscularly)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Constant infusion of 7 U/h in albumin-free saline (0.44 U/kg loading dose intravenously)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 30
Study: 29890865

Group type: EXPERIMENTAL
Intervention: CFA plus recombinant FSH after day 8 (CFA-plus group)
Number of subjects: 268

Group type: COMPARATOR
Intervention: CFA-only
Number of subjects: 268
Study: 26880570

Group type: EXPERIMENTAL
Intervention: First-generation DES
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: Second-generation DES
Number of subjects: 1259

Group type: COMPARATOR
Intervention: DAPT continuation (6 to 18 additional months)
Number of subjects: 1259

Group type: COMPARATOR
Intervention: DAPT interruption (aspirin only)
Number of subjects: 1259
Study: 24582053

Group type: EXPERIMENTAL
Intervention: DB ACLR with suturing of the ruptured tissue to hamstring graft (n = 5)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional DB ACLR (n = 5)
Number of subjects: 10
Study: 23034698

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 157

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 157
Study: 21223673

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture therapy (AAT) on active points
Number of subjects: 125

Group type: COMPARATOR
Intervention: AAT on sham points (control group)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Comparison between AAT on active points and AAT on sham points
Number of subjects: 125
Study: 18520389

Group type: EXPERIMENTAL
Intervention: Haas expander
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hyrax expander
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups (Haas and Hyrax)
Number of subjects: 38
Study: 16415999

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 5 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 10 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 20 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 40 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 60 mg
Number of subjects: 42
Study: 11839712

Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.3 pmol/kg/min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.9 pmol/kg/min
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 11
Study: 10585387

Group type: EXPERIMENTAL
Intervention: Long Walkers (LW; 20-40 min/bout)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intermediate Walkers (IW; 10-15 min/bout)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Short Walkers (SW; 5-10 min/bout)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 56
Study: 7538555

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 5 micrograms/kg/d beginning on day + 1 following transplant
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard posttransplant supportive care without HGF
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: G-CSF in patients who received PBSC alone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control in patients who received PBSC alone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: G-CSF in patients who received PBSC with bone marrow
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control in patients who received PBSC with bone marrow
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 2157240

Group type: EXPERIMENTAL
Intervention: High dose proton treatment
Number of subjects: 50
Study: 7003869

Group type: EXPERIMENTAL
Intervention: Immediate node dissection
Number of subjects: 553

Group type: COMPARATOR
Intervention: Delayed node dissection
Number of subjects: 553
Study: 30999679

Group type: EXPERIMENTAL
Intervention: Real neck taping for 30 consecutive days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham neck taping for 30 consecutive days
Number of subjects: 12
Study: 27977473

Group type: EXPERIMENTAL
Intervention: Bremelanotide 1.25 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Bremelanotide 1.75 mg
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 25445335

Group type: EXPERIMENTAL
Intervention: Structured brief advice based on the 5 A's model
Number of subjects: 467

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 467
Study: 23415629

Group type: EXPERIMENTAL
Intervention: Telephone coaching adherence intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 54
Study: 20465356

Group type: EXPERIMENTAL
Intervention: Increased perceptual selection demands (ventral regions activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased action selection demands (dorsal regions activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased action selection demands (lateral pFC activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choice response times
Number of subjects: 0
Study: 19897780

Group type: EXPERIMENTAL
Intervention: Individually tailored programs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 17222848

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes without plaques
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes with atherosclerotic plaques
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 120
Study: 15209651

Group type: EXPERIMENTAL
Intervention: Osteoporosis screening program participants
Number of subjects: 9268

Group type: COMPARATOR
Intervention: Nonparticipants of osteoporosis screening program
Number of subjects: 9268
Study: 10873400

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemoradiation (inpatient setting)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemoradiation (outpatient setting)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy using radiation alone
Number of subjects: 0
Study: 9524790

Group type: EXPERIMENTAL
Intervention: 0.025% azelastine eye drops
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 0.05% azelastine eye drops
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 8249563

Group type: EXPERIMENTAL
Intervention: 2 mg of morphine in saline
Number of subjects: 12

Group type: COMPARATOR
Intervention: saline only
Number of subjects: 12
Study: 2411072

Group type: EXPERIMENTAL
Intervention: Topical application of 10% zinc sulfate in Aquaphor ointment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Aquaphor alone
Number of subjects: 47
Study: 31256912

Group type: EXPERIMENTAL
Intervention: Monolithic lithium disilicate occlusal onlays
Number of subjects: 7
Study: 29941520

Group type: EXPERIMENTAL
Intervention: Plasma renin activity (PRA) at 28 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Plasma renin activity (PRA) at 36 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Urine aldosterone (Ualdo) at 28 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PRA and Ualdo correlation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PRA and Ualdo in women of black race
Number of subjects: 108
Study: 25988938

Group type: EXPERIMENTAL
Intervention: Needle-free powder lidocaine delivery system
Number of subjects: 693

Group type: COMPARATOR
Intervention: Sham placebo
Number of subjects: 693
Study: 25033919

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture (twice a week for 4 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Solifenacin, Acupuncture, Placebo
Number of subjects: 90
Study: 23043381

Group type: EXPERIMENTAL
Intervention: Moderate exercise group (150 minutes of moderate to vigorous physical activity per week for six weeks)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Extensive exercise group (300 minutes of moderate to vigorous physical activity per week for six weeks)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no instructions regarding lifestyle)
Number of subjects: 146
Study: 20728565

Group type: EXPERIMENTAL
Intervention: High-protein/high red meat (HP) diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) diet
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (non-weight-loss)
Number of subjects: 33
Study: 18612188

Group type: EXPERIMENTAL
Intervention: Fluvastatin, 80 mg/day, orally for 6 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (lifestyle modification only)
Number of subjects: 85
Study: 16037178

Group type: EXPERIMENTAL
Intervention: RM group (0.25% ropivacaine and morphine 0.2 mg/mL)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RMK group (0.25% ropivacaine, morphine 0.2 mg/mL and ketorolac 1 mg/mL)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 39
Study: 11922560

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily (n = 93)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Mesalazine 2 g b.i.d. (n = 89)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily
Number of subjects: 182

Group type: COMPARATOR
Intervention: Mesalazine 2 g b.i.d.
Number of subjects: 182
Study: 10961629

Group type: EXPERIMENTAL
Intervention: Epilepsy nurse specialist
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 90
Study: 8780276

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine 2 micrograms/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine 4 micrograms/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous buprenorphine 2 micrograms/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous buprenorphine 4 micrograms/kg
Number of subjects: 50
Study: 1632979

Group type: EXPERIMENTAL
Intervention: Natural leukocyte alpha interferon (IFN) administered at 6 MU i.m. daily for 4 weeks and thereafter 3 times per week for 2 months, combined with radiotherapy (2 Gy daily, 5 fractions per week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Radiotherapy alone (control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Natural leukocyte alpha interferon (IFN)
Number of subjects: 22
Study: 6708391

Group type: EXPERIMENTAL
Intervention: Digoxin administration (plasma levels 1.55 +/‐ 0.27 ng/ml) lasting 35 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Digoxin administration with maximal stimulation of adrenal and gonadal glands by ACTH and hCG
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Digoxin administration over a period of 150‐210 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Beta‐methyldigoxin, beta‐acetyldigoxin, and digitoxin (mean duration: 1.9 years)
Number of subjects: 43
Study: 31900148

Group type: EXPERIMENTAL
Intervention: Clinical laboratory services satisfaction survey
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Dissatisfaction factors
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Educational status and distance
Number of subjects: 2399
Study: 31885908

Group type: EXPERIMENTAL
Intervention: 10,000 steps
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 12,500 steps
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 15,000 steps
Number of subjects: 92

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 92
Study: 28302130

Group type: EXPERIMENTAL
Intervention: Distraction arthroplasty combined with arthroscopic microfracture
Number of subjects: 96

Group type: COMPARATOR
Intervention: Distraction arthroplasty alone
Number of subjects: 96
Study: 26363127

Group type: EXPERIMENTAL
Intervention: Lidcombe Program
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Demands and Capacities-based treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Lidcombe Program and Demands and Capacities-based treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Participation in RESTART-trial
Number of subjects: 13
Study: 23517837

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 7021

Group type: EXPERIMENTAL
Intervention: Radial access (low volume centers)
Number of subjects: 7021

Group type: EXPERIMENTAL
Intervention: Radial access (middle volume centers)
Number of subjects: 7021

Group type: EXPERIMENTAL
Intervention: Radial access (high volume centers)
Number of subjects: 7021

Group type: EXPERIMENTAL
Intervention: Procedural volume
Number of subjects: 7021
Study: 21474646

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study: 17994292

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg/day)
Number of subjects: 27179

Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg/day)
Number of subjects: 27179

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27179
Study: 16426960

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified beverage
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study: 12601257

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration (CVVHDF) during radiological procedures (RxP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Historical controls (not receiving CVVHDF)
Number of subjects: 26
Study: 11512693

Group type: EXPERIMENTAL
Intervention: JOAS
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: AOAS
Number of subjects: 81

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 81
Study: 9640080

Group type: EXPERIMENTAL
Intervention: Zinc protoporphyrin (ZPP) measurement in patients with iron deficiency
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Zinc protoporphyrin (ZPP) measurement in patients with ACD
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination of ZPP measurement with ferritin and peripheral blood morphology
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Zinc protoporphyrin (ZPP) level higher than 4.55 micrograms/gHb
Number of subjects: 96
Study: 8102829

Group type: EXPERIMENTAL
Intervention: Vecuronium doses ranging from 0.1 to 0.3 mg kg‐1
Number of subjects: 0
Study: 3813189

Group type: EXPERIMENTAL
Intervention: Urapidil (0.75 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hydralazine (0.35 mg/kg)
Number of subjects: 10
Study: 2628130

Group type: EXPERIMENTAL
Intervention: Ampicillin bound to sulbactam (sultamicillin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amoxycillin with clavulanic acid
Number of subjects: 16
Study: 31348248

Group type: EXPERIMENTAL
Intervention: Sogyeonghwalhyeol-tang
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 28750894

Group type: EXPERIMENTAL
Intervention: Torus printlet
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Capsule and disc shaped printlets
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sphere printlet
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Smaller printlet sizes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Printlet colour
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall acceptability of torus printlets
Number of subjects: 50
Study: 25138115

Group type: EXPERIMENTAL
Intervention: Spinomed orthosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osteomed orthosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinomed active orthosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spine-X orthosis
Number of subjects: 0
Study: 23041092

Group type: EXPERIMENTAL
Intervention: High vWF/ADAMTS13-ratio (>27.57)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: ADAMTS13 ≤ 49.77%
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: vWF > 1434.92 mU/ml
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: High vWF/ADAMTS13-ratio (>27.57) in low and intermediate risk patients (according to CHADS2-score)
Number of subjects: 269
Study: 21474219

Group type: EXPERIMENTAL
Intervention: EPA-GLA diet
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 160
Study: 17947225

Group type: EXPERIMENTAL
Intervention: Cetuximab plus cisplatin/vinorelbine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cisplatin/vinorelbine alone
Number of subjects: 86
Study: 16492211

Group type: EXPERIMENTAL
Intervention: Blood ketone monitoring (blood glucose monitor that also measures blood 3-OHB)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Urine ketone testing (monitor plus urine ketone strips)
Number of subjects: 123
Study: 15106359

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (calcium 1000 mg/day)
Number of subjects: 90
Study: 11334476

Group type: EXPERIMENTAL
Intervention: Combiphasic EE/DSG (25 microg desogestrel and 40 microg ethinylestradiol for 7 days followed by 125 microg desogestrel and 30 microg ethinylestradiol for 15 days)
Number of subjects: 172

Group type: COMPARATOR
Intervention: EE35/CPA (2.0 mg cyproterone acetate and 35 microg ethinylestradiol for 21 days)
Number of subjects: 172
Study: 9127977

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (twice-weekly sessions of low intensity movements for one year)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 110
Study: 7525246

Group type: EXPERIMENTAL
Intervention: Direct cortical recordings of ERD and MRCPs during self-paced finger movements
Number of subjects: 23

Group type: COMPARATOR
Intervention: Scalp-recorded EEGs
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Analysis of ERD responses in frequency bands (8-10 Hz, 10-12 Hz, 12-20 Hz, 20-30 Hz)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Comparison of ERD response magnitude and MRCP peak amplitude
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Timing and topographical features of ERD responses
Number of subjects: 23
Study: 3679574

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) in acute idiopathic radiculopolyneuropathies
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) in chronic idiopathic radiculopolyneuropathies
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) in Guillain-Barré syndrome
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 62
Study: 29343303

Group type: EXPERIMENTAL
Intervention: Modified wet suction technique (MWST)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Dry suction technique (DRST)
Number of subjects: 296
Study: 26340656

Group type: EXPERIMENTAL
Intervention: Craniosacral Therapy (CST)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Light-touch sham treatment
Number of subjects: 54
Study: 25258523

Group type: EXPERIMENTAL
Intervention: IG/HD + RCH (210 g of ricotta cheese daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CG/HD (habitual diet only)
Number of subjects: 0
Study: 22682721

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally 24 hours prior to abortion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Osmotic dilators
Number of subjects: 50
Study: 20202538

Group type: EXPERIMENTAL
Intervention: Correction for posture-related ocular cyclotorsion
Number of subjects: 102

Group type: COMPARATOR
Intervention: No correction for posture-related ocular cyclotorsion
Number of subjects: 102